Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Incyte Corporation    INCY   US45337C1027

INCYTE CORPORATION (INCY)

25
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on INCYTE CORPORATION
7d ago INCYTE : 'Nashville' Star Charles Esten Shares Personal Experience in Battling R..
12/09 INCYTE : Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial ..
12/09 NOVARTIS : announces safety and efficacy benefit of Jakavi in global clinical tr..
12/09 INCYTE : Secures FDA Approval for Jakafi (ruxolitinib)
12/05 INCYTE : CURE Magazine and Incyte Honor MPN Heroes
12/04 INCYTE : FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with U..
12/02 INCYTE : Multiple Data Presentations at the 2014 American Society of Hematology ..
11/28 INCYTE : Assigned Patent
11/26 INCYTE : Patent Issued for Metabolites of the Janus Kinase Inhibitor ®-3-(4-(7H-..
11/26 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
11/26 INCYTE : CURE Magazine and Incyte to Honor MPN Heroes
11/21 INCYTE : Assigned Patent
11/18 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
11/17 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
11/17 INCYTE : to Present at Upcoming Investor Conferences
11/14 INCYTE : Assigned Patent
11/05 INCYTE : Reports 2014 Third-Quarter Financial Results and Updates Shareholders o..
11/04 INCYTE : Posts 2014 3Q Financial Results
10/31 INCYTE : Assigned Patent
10/31 INCYTE : Assigned Patent
10/30 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
10/30 INCYTE : beats Street 3Q forecasts
10/30 INCYTE : Results of Operations and Financial Condition, Financial Statements and..
10/30 INCYTE : Reports 2014 Third-Quarter Financial Results and Updates Shareholders o..
10/29 INCYTE : to Present at the Nomura BioPharma Conference
10/23 INCYTE : to Present at the Nomura BioPharma Conference
10/20 INCYTE : Change in Directors or Principal Officers, Financial Statements and Exh..
10/18 INCYTE : Gets Payment Related to Reimbursement of Jakavi (ruxolitinib)
10/17 INCYTE : Appoints David Gryska as Executive Vice President and Chief Financial O..
10/15 INCYTE : to Report Third Quarter 2014 Financial Results on October 30
10/08 INCYTE : Earns $60 Million Milestone Related to Reimbursement of Jakavi® ruxolit..
10/07 INCYTE : Garners Payment Related to Reimbursement of Jakavi (ruxolitinib)
10/02 INCYTE : Other Events, Financial Statements and Exhibits (form 8-K)
10/02 INCYTE : Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxoli..
09/26 INCYTE : Assigned Patent
09/19 INCYTE : Assigned Patent
09/17 INCYTE : Patent Issued for Salts of the Janus Kinase Inhibitor ®-3-(4-(7H-Pyrrol..
09/17 INCYTE : Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called ..
09/17 INCYTE : to Present at the 21st Annual BioCentury NewsMakers Conference
09/12 INCYTE : Assigned Patent
09/10 INCYTE : Patent Issued for Salts of the Janus Kinase Inhibitor ®-3-(4-(7H-Pyrrol..
09/08 INCYTE : to Present at the 21st Annual BioCentury NewsMakers Conference
09/08 INCYTE : Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called ..
09/05 TETRALOGIC PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Delaware (Sept..
09/05 INCYTE : Assigned Patent
08/28 INCYTE : Diagnostics lab makes yet another acquisition
08/21 INCYTE : Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, Immu..
08/14 INCYTE : Secures FDA sNDA for Jakafi (ruxolitinib)
08/08 INCYTE : Gets FDA sNDA for Jakafi (ruxolitinib)
08/07 INCYTE : Assigned Patent
08/06 INCYTE : Announces Clinical Trial Agreement to Evaluate Combination of Two Novel..
08/05 INCYTE : FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib)..
08/01 Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders..
07/31 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
07/31 INCYTE : Results of Operations and Financial Condition, Financial Statements and..
07/31 INCYTE : Reports 2014 Second-Quarter Financial Results and Updates Shareholders ..
07/30 INCYTE : Announces Clinical Trial Agreement to Evaluate Combination of Two Novel..
07/29 INCYTE : Assigned Patent
07/28 INCYTE : Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Surviva..
07/23 INCYTE : Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients..
07/18 INCYTE : Gets $25 Million Milestone Payment for Approval of Jakavi (ruxolitinib)..
07/17 INCYTE : Leadership Appointments, Earnings Conference Calls, Milestone Payments,..
07/16 INCYTE : Achieves $25 Million Milestone for Approval of Jakavi® ruxolitinib in J..
07/14 INCYTE : to Report Second Quarter 2014 Financial Results on July 31
07/11 INCYTE : Earns $25 Million Milestone Payment for Approval of Jakavi (ruxolitinib..
07/08 INCYTE : Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in..
07/03 INCYTE : Assigned Patent
07/02 INCYTE : Lab here acquires Yakima pathology services group
06/27 INCYTE : Assigned Patent
06/23 INCYTE : Assigned Patent
06/19 INCYTE : Patent Issued for Hydroxyl, Keto, and Glucuronide Derivatives of 3-(4-(..
06/18 INCYTE : to Present at the 9th Annual JMP Securities Healthcare Conference
06/13 INCYTE : Assigned Patent
06/13 GERON : GERN) Gains After FDA Green Lights Imetelstat Trial Resumption
06/12 INCYTE : to Present at the 9th Annual JMP Securities Healthcare Conference
1  2  3  4  5Next
Advertisement
Chart
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF